• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
EGRX

EGRX

Eagle Pharmaceuticals, Inc.

OTCHealthcareDrug Manufacturers - Specialty & GenericUS

USD0.46

-0.12 (-20.00%)

Company Profile

CEO

Michael Graves

IPO Date

2014-02-12

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

OTC

Country

US

Market Metrics

Open

$0.01

Prev. Close

$0.57

Day Low

$0.01

Day High

$0.47

52W Low

$0.09

52W High

$3.87

Market Cap

$0.01B

Volume

0.01M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

40.0%

Avg Negative

14.3%

Avg Neutral

45.7%

News Feed

Eagle Pharmaceuticals Wins Vasopressin Patent Trial

Business Wire·8/31/2021·↓ negative

Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise

Business Wire·8/31/2021·↑ positive

Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia

Business Wire·8/25/2021·↑ positive

Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus

Benzinga·8/9/2021·↑ positive

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tariff on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/9/2021·↓ negative

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research·8/9/2021·↑ positive

Eagle Pharmaceuticals Reports Second Quarter 2021 Results

Business Wire·8/9/2021·↑ positive

Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker

Business Wire·8/9/2021·↑ positive

Eagle Pharmaceuticals: A Potential Reopening Play

Seeking Alpha·6/16/2021·↓ negative

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Eagle Pharmaceuticals, Inc.- EGRX

Newsfile Corp·6/11/2021·↓ negative